(RTTNews) - NurExone Biologic Inc. (NRX), Friday reported its third-quarter 2025 financial results and provided a corporate update highlighting pipeline progress and upcoming milestones.
The company's lead program is ExoPTEN, an exosome-based therapy targeting PTEN inhibition for acute spinal cord injury. ExoPTEN is currently in preclinical development, with additional indications under investigation including glaucoma, facial/CNS traumatic injury (via PNN targeting sequence), and chronic spinal cord injury.
Preclinical data announced in October demonstrated dose-dependent improvements in motor recovery and retinal function, positioning ExoPTEN as a potential first-in-class therapy.
NurExone plans to submit an IND application in 2026 to advance ExoPTEN into clinical trials.
In addition to ExoPTEN, NurExone is advancing ExoTherapy, a broader platform leveraging exosomes and stem cells for regenerative medicine. The company is also collaborating with Inteligex, which provides a novel targeted human stem cell platform designed to replace key cell types lost due to traumatic injury or neurodegeneration.
During the quarter, NurExone strengthened its intellectual property portfolio. On September 8, 2025, the company received a Notice of Allowance from the U.S. Patent and Trademark Office for its proprietary exosome manufacturing process, covering its 3D scaffold and shear- stress- based bioreactor system. The patent was formally granted on November 11, 2025, alongside a corresponding grant in Israel.
The company also announced plans to establish its first U.S. commercial exosome production facility in Indianapolis, Indiana, through its subsidiary Exo-Top Inc., supported by an incentive offer of up to $0.26 million.
The GMP-compliant facility will serve as a U.S. manufacturing base for NurExone's therapeutic programs and business-to-business opportunities in regenerative aesthetics.
NurExone enhanced its global visibility through invited presentations at leading exosome and regenerative medicine meetings, including the Precision EV Forum 2025 in Cambridge, U.K. CEO Dr. Lior Shaltiel has been invited to speak at the Upcoming Cell and Gene Therapy International Europe Conference in Berlin in December.
The company was named a finalist in two international award programs - the Falling Walls Science Breakthroughs (Berlin, November 2025) and the Prix Galien Bridges Awards (Stockholm)- underscoring the innovation of its exosome-based therapies.
An investor webinar is scheduled for December 10, 2025, to discuss recent achievements, U.S. biomanufacturing expansion, and strategic priorities for 2026.
Q3 Financials:
Net R&D expenses were $0.70 million in Q3 2025, compared to $0.50 million in Q3 2024.
G&A expenses were $0.76 million, slightly down from $0.78 million in the prior-year quarter.
Net loss widened to $1.47 million in Q3 2025, compared to $1.25 million in Q3 2024.
The company raised C$1.4 million through private placements in August and September 2025 and secured C$3.2 million in gross proceeds from accelerated warrant exercises in November.
NRX.NE is currently trading at $0.70, down 1.41%. Over the past 12 months the stock has traded between $0.54 to $1.14.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
